IL17A and rheumatoid arthritis: Although previous clinical trials in patients with rheumatoid arthritis showed a benefit of blocking IL-17A with secukinumab, a phase 2 clinical trial that enrolled patients with active CD demonstrated that IL-17A blockade is ineffective and leads to higher rates of adverse events than treatment with a placebo [100].